Calprotectin in inflammatory bowel disease
Data
2020Autor
Khaki-Khatibi, Fatemeh
Qujeq, Durdi
Kashifard, Mehrdad
Moein, Soheila
Maniati, Mahmood
Vaghari-Tabari, Mostafa
Metadata
Mostrar registro completo
Documentos PDF
Imagenes y Videos
Resumo
The term IBD is usually used for referring to a group of inflammatory gastro-intestinal diseases (mainly
Crohn's disease and ulcerative colitis). Accordingly, IBD arises as a result of inappropriate immune
response to intestinal commensal organisms among genetically susceptible individuals. Performing
colonoscopy and histopathologic evaluation on an inflamed bowel biopsy specimen are currently
considered as gold standards for diagnosis and management of IBD. Correspondingly, these techniques
are known to be invasive and costly. In recent decades, fecal calprotectin, as a biomarker, has received
much attention for the diagnosis and non-invasive management of IBD. Up to now, many studies have
investigated the efficacy of fecal calprotectin in the areas of IBD differentiation from IBS, prediction of
endoscopic and histologic activities of IBD and prediction of disease recurrence. Although some of
these studies have reported promising results, some others have shown significant limitations. Therefore,
in this paper, we reviewed the most interesting ones of these studies after a brief discussion of the
laboratory measurement of fecal calprotectin. Moreover, we attempted to provide an answer for the
question of whether fecal-calprotectin could be considered as a potential surrogate marker for
colonoscopy.
Palabras clave
IBD; Fecal calprotectin; Endoscopic activity; IBD non-invasive managementLink para o recurso
https://doi.org/10.1016/j.cca.2020.08.025Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.